PA
GTHX

Parallel Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Parallel Advisors’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-50
Closed -$72 – 3501
2023
Q3 		$72 Hold
50
– – ﹤0.01% 3297
2023
Q2 		$125 Hold
50
– – ﹤0.01% 3271
2023
Q1 		$134 Hold
50
– – ﹤0.01% 3313
2022
Q4 		$272 Hold
50
– – ﹤0.01% 3140
2022
Q3 		$1K Buy
+50
New +$571 ﹤0.01% 3063

Other funds holding GTHX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Parallel Advisors's GTHX Position: Q4 2023 in Review

Parallel Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2023, closing a stake of 50 shares — an estimated $72 sold.

Parallel Advisors first reported a position in GTHX in Q3 2022 and held it in 5 quarters. The position peaked at $1K in Q3 2022. 87 funds tracked by Wall St. Rank hold GTHX as of Q4 2023.

  • Parallel Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Parallel Advisors sold 50 G1 Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $72.
  • Parallel Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2022 and held it in 5 quarters.
  • Parallel Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $1K in Q3 2022.
  • 87 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Parallel Advisors's 13F filing for Q4 2023, filed 12 Feb 2024.